首页 产品中心 抗体 生化试剂 研究领域
服务与支持 定制服务 技术支持 促销活动 关于我们
登 录 注 册

GSK3 alpha/beta (YD14262) Rabbit mAb  (货号:AYD11332)

A
小A 扫码咨询
宿主: Rabbit克隆性: Monoclonal反应: Human,Mouse,RatWBIHC-PICC/IFFCIP
货号 AYD11332
靶点/基因 GSK3A/GSK3B
宿主 Rabbit
克隆性 Monoclonal
反应种属 Human, Mouse, Rat
应用 WB, IHC-P, ICC/IF, FC, IP

货号:AYD11332

规格价格
50ul ¥1280.00 加购物车
100ul ¥2300.00 加购物车
  • 产品信息

  • 应用指南

  • 相关产品

  • 抗原信息

  • 靶点信息

  • 资料与支持

  • 实验步骤

  • 常见问题

反应 Human,Mouse,Rat
宿主 Rabbit
克隆性 Monoclonal
同种型 IgG
应用 WBIHC-PICC/IFFCIP
推荐浓度
理论分子量 51kDa/47kDa
实测分子量
形式 Liquid
保存条件 Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.75% BSA,50% glycerol,pH7.3.
偶联物 Unconjugated
阳性对照
细胞定位 Cytoplasm, Nucleus, Cell membrane
纯化 亲和纯化

应用与推荐条件

快速判断怎么用

以下条件基于推荐浓度、验证图说明与通用实验要求整理,可作为预实验起点;不同样本和检测体系建议做梯度优化。

WB WB 推荐条件
推荐稀释 请参考验证图说明或咨询技术支持
建议样本/阳性对照 建议选择靶点高表达样本作为阳性对照
关键条件 建议使用新鲜裂解样本,按推荐稀释比例孵育一抗,并关注理论/实测分子量
预期结果 预期信号/条带约 51kDa/47kDa
对照设置 建议设置阳性样本、阴性样本和二抗/同型对照
IHC-P IHC-P 推荐条件
推荐稀释 请参考验证图说明或咨询技术支持
建议样本/阳性对照 建议选择靶点高表达样本作为阳性对照
关键条件 石蜡切片建议优化抗原修复液 pH、修复时间和一抗孵育条件
预期结果 预期定位:Cytoplasm, Nucleus, Cell membrane
对照设置 建议设置阳性样本、阴性样本和二抗/同型对照
ICC/IF ICC/IF 推荐条件
推荐稀释 请参考验证图说明或咨询技术支持
建议样本/阳性对照 建议选择靶点高表达样本作为阳性对照
关键条件 建议优化固定、通透和封闭条件,并设置二抗空白对照
预期结果 预期荧光定位:Cytoplasm, Nucleus, Cell membrane
对照设置 建议设置阳性样本、阴性样本和二抗/同型对照
FC FC 推荐条件
推荐稀释 请参考验证图说明或咨询技术支持
建议样本/阳性对照 建议选择靶点高表达样本作为阳性对照
关键条件 如检测胞内靶点,需优化固定/通透条件,并设置同型对照
预期结果 预期阳性群体荧光信号相对阴性/同型对照右移
对照设置 建议设置阳性样本、阴性样本和二抗/同型对照
IP IP 推荐条件
推荐稀释 请参考验证图说明或咨询技术支持
建议样本/阳性对照 建议选择靶点高表达样本作为阳性对照
关键条件 建议从页面推荐浓度开始,结合样本与检测体系做梯度优化
预期结果 预期信号/条带约 51kDa/47kDa
对照设置 建议设置阳性样本、阴性样本和二抗/同型对照

相关产品

查找相关产品 >>

抗原信息

抗原信息 请咨询 技术支持
序列 Email For Sequence

靶点信息

研究背景 Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1 (PubMed:11749387, PubMed:17478001, PubMed:19366350). Requires primed phosphorylation of the majority of its substrates (PubMed:11749387, PubMed:17478001, PubMed:19366350). Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis (PubMed:11749387, PubMed:17478001, PubMed:19366350). Regulates glycogen metabolism in liver, but not in muscle (By similarity). May also mediate the development of insulin resistance by regulating activation of transcription factors (PubMed:10868943, PubMed:17478001). In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin (PubMed:17229088). Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease (PubMed:12761548). May be involved in the regulation of replication in pancreatic beta-cells (By similarity). Is necessary for the establishment of neuronal polarity and axon outgrowth (By similarity). Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation (By similarity). Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions which activates KAT5/TIP60 acetyltransferase activity and promotes acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer (PubMed:30704899). Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation (By similarity). Phosphorylates mTORC2 complex component RICTOR at 'Thr-1695' which facilitates FBXW7-mediated ubiquitination and subsequent degradation of RICTOR (PubMed:25897075) Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1 (PubMed:11430833, PubMed:12554650, PubMed:14690523, PubMed:16484495, PubMed:1846781, PubMed:20937854, PubMed:9072970). Requires primed phosphorylation of the majority of its substrates (PubMed:11430833, PubMed:16484495). In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis (PubMed:8397507). May also mediate the development of insulin resistance by regulating activation of transcription factors (PubMed:8397507). Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase (PubMed:8397507). In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes (PubMed:12554650). Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA (PubMed:1846781). Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin (PubMed:9072970). Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules (PubMed:14690523). MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease (PubMed:14690523). Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex (PubMed:20937854). Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair (By similarity). Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF (TNF/TNFA) (By similarity). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes (By similarity). Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation (By similarity). Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin (PubMed:9819408). Is necessary for the establishment of neuronal polarity and axon outgrowth (PubMed:20067585). Phosphorylates MARK2, leading to inhibition of its activity (By similarity). Phosphorylates SIK1 at 'Thr-182', leading to sustainment of its activity (PubMed:18348280). Phosphorylates ZC3HAV1 which enhances its antiviral activity (PubMed:22514281). Phosphorylates SNAI1, leading to its ubiquitination and proteasomal degradation (PubMed:15448698, PubMed:15647282, PubMed:25827072, PubMed:29059170). Phosphorylates SFPQ at 'Thr-687' upon T-cell activation (PubMed:20932480). Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including BMAL1, CLOCK and PER2 (PubMed:19946213, PubMed:28903391). Phosphorylates FBXL2 at 'Thr-404' and primes it for ubiquitination by the SCF(FBXO3) complex and proteasomal degradation (By similarity). Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation (PubMed:19946213). Phosphorylates BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation (PubMed:28903391). Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509). Regulates the circadian rhythmicity of hippocampal long-term potentiation and BMAL1 and PER2 expression (By similarity). Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, activating KAT5/TIP60 acetyltransferase activity and promoting acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer (PubMed:30704899). Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation (PubMed:18846110). Phosphorylates E2F1, promoting the interaction between E2F1 and USP11, stabilizing E2F1 and promoting its activity (PubMed:17050006, PubMed:28992046). Phosphorylates mTORC2 complex component RICTOR at 'Ser-1235' in response to endoplasmic stress, inhibiting mTORC2 (PubMed:21343617). Phosphorylates mTORC2 complex component RICTOR at 'Thr-1695' which facilitates FBXW7-mediated ubiquitination and subsequent degradation of RICTOR (PubMed:25897075). Phosphorylates FXR1, promoting FXR1 ubiquitination by the SCF(FBXO4) complex and FXR1 degradation by the proteasome (By similarity). Phosphorylates interleukin-22 receptor subunit IL22RA1, preventing its proteasomal degradation (By similarity). Phosphorylates and inhibits the CTP synthase and protein-asparagine deamidase activities of CTPS1 (PubMed:17681942). Phosphorylates DSP at multiple sequential serine residues in the C-terminus tail, promoting its recruitment to developing desmosome cell-cell junctions (PubMed:25733715)
基因 ID 2931, 2932
基因名 GSK3A, GSK3B
Swiss P49840, P49841
别名 GSK3 alpha/beta (YD14262),GSK3 alpha/beta (YD14262) Rabbit mAb,GSK3A,GSK3B,Serine/threonine-protein kinase GSK3A,Serine/threonine-protein kinase GSK3B

资料与技术支持

验证数据

2 张验证图

页面顶部轮播可查看应用验证图,覆盖 WB / IHC-P / ICC/IF / FC / IP。

文献引用

暂无公开文献关联,欢迎联系技术支持获取更多应用案例。

咨询案例
客户评价

暂无客户评价,使用后可提交评价与实验图片。

提交反馈
技术支持

可协助确认应用、样本、稀释比例、阳性/阴性对照和实验条件。

进入支持中心
需要确认应用条件?

请提供货号 AYD11332、实验应用、样本类型和检测体系,技术支持可协助确认稀释比例、阳性/阴性对照和 COA/批次资料。

常见问题

当前页面标注应用包括 WB, IHC-P, ICC/IF, FC, IP,建议结合页面验证图和推荐稀释比例进行预实验优化。
可通过页面询价/留言入口提交货号和批号,技术支持会协助提供对应批次资料。
页面推荐条件可作为起始浓度,不同样本、固定方式和检测体系可能需要梯度优化。

实验步骤

实验步骤
AYD11332